Literature DB >> 24124110

ZAP70 in B-CLL cells related to the expression in NK cells is a surrogate marker for mutational status.

Tom G H Wiggers1, Guus Westra, Theresia M Westers, Andre P Abbes, Annuska Strunk, Ellen Kuiper-Kramer, Pino Poddighe, Arjan A van de Loosdrecht, Martine E D Chamuleau.   

Abstract

The strongest prognostic factor in chronic B-cell lymphocytic leukaemia (CLL) is the mutational status of the immunoglobulin heavy chain variable region (IGHV) genes. Determination of this mutational status is laborious and therefore not applied in routine diagnostics. A search for 'surrogate markers' has been conducted over the past few years. One of the most promising surrogate markers is ZAP70, but standardisation of the measurement of ZAP70 has proven to be difficult. Conventionally, ZAP70 expression in CLL cells is related to ZAP70 expression in T cells. We propose a new method in which ZAP70 expression in NK cells is used as reference (new NK-MFI method). We have measured ZAP70 expression in samples of 45 previously untreated CLL patients. ZAP70 in CLL cells related to ZAP70 in NK cells correlated better to cytogenetic risk profile and mutational status than the conventional methods. Negativity of both ZAP70 (new NK-MFI method) and CD38 resulted in a probability of 90% for mutated IGHV genes. In conclusion, ZAP70 expression in CLL cells related to ZAP70 expression in NK cells is a better surrogate marker for mutational status than the conventional T cell related methods. © 2013 Clinical Cytometry Society.
Copyright © 2013 Clinical Cytometry Society.

Entities:  

Keywords:  CD38; NK cells; ZAP70; chronic lymphocytic leukaemia; mutational status; prognosis

Year:  2013        PMID: 24124110     DOI: 10.1002/cytob.21132

Source DB:  PubMed          Journal:  Cytometry B Clin Cytom        ISSN: 1552-4949            Impact factor:   3.058


  1 in total

1.  ZAP70 Expression Within del6q21, del11q13 and del17p13 Cytogenetic Subgroups of Iranian Patients with Chronic Lymphocytic Leukemia.

Authors:  Hamideh Jafari Ghahfarokhi; Saeede Ashoori; Mohamad Taghi Akbari; Masoud Lotfizadeh; Ali Karimi; Hossein Teimori
Journal:  Iran Red Crescent Med J       Date:  2014-11-16       Impact factor: 0.611

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.